Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 30;11(10):354.
doi: 10.21037/atm-22-4218. Epub 2023 May 23.

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review

Alejandro Olivares-Hernández  1   2 , Elísabet González Del Portillo  3 , Álvaro Tamayo-Velasco  4 , Luis Figuero-Pérez  1   2 , Svetlana Zhilina-Zhilina  5 , Emilio Fonseca-Sánchez  1   2   6 , José Pablo Miramontes-González  7   8
Affiliations
Review

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review

Alejandro Olivares-Hernández et al. Ann Transl Med. .

Abstract

Background: The introduction of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) has resulted in a radical change in patients' treatment responses and survival rates. The increased percentage of long survivors, improved toxicity profiles compared to chemotherapy, and the possible applications for different NSCLC scenarios, have led to immune checkpoint inhibitors (ICIs) becoming the cornerstone of NSCLC treatment. Therefore, the objective of this review is to describe the current and future perspectives of NSCLC treatment.

Methods: A systematic review according to the PRISMA criteria has been performed based on clinical trials with immunotherapy in NSCLC from the start of these treatments until June 2022.

Results: The use of ICIs is widespread across both first- and second-line treatments with anti-PD-1, anti-PD-L1, and anti-CTLA-4 drugs. New indications for immunotherapy in NSCLC have focused on adjuvant (atezolizumab) and neoadjuvant (nivolumab), with ICIs now present in all stages of NSCLC treatment. Given the promising results seen in clinical trials, new ICIs [anti- lymphocyte activation gene-3 (LAG-3) or IDO1] currently under development, will soon be used as standard treatment for NSCLC.

Conclusions: Immunotherapy is the mainstay of NSCLC treatment in all stages, including adjuvant, neoadjuvant and advanced tumors. The development of new molecules will revolutionize the treatment of NSCLC in the coming years.

Keywords: anti-CTLA-4; anti-PD-1; anti-PD-L1; immune checkpoint inhibitors (ICIs); non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-4218/coif). JPMG serves as an unpaid editorial board member of Annals of Translational Medicine from June 2022 to May 2024. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Development of the different ICIs along the last 10 years to nowadays in NSCLC. 2L, second-line; sq, squamous; NSCLC, non-small cell lung cancer; 1L, first-line; CT, chemotherapy; RT, radiotherapy; ICIs, immune checkpoint inhibitors.
Figure 2
Figure 2
Flow diagram of selected included and excluded studies.
See this image and copyright information in PMC

Comment in

References

    1. Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis. Int J Mol Sci 2021;22:8661. 10.3390/ijms22168661 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33. 10.3322/caac.21654 - DOI - PubMed
    1. Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treat Res 2016;170:47-75. 10.1007/978-3-319-40389-2_3 - DOI - PubMed
    1. Tsao AS, Scagliotti GV, Bunn PA, Jr, et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol 2016;11:613-38. 10.1016/j.jtho.2016.03.012 - DOI - PubMed